Cargando…

Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C

Pegylated-interferon plus ribavirin is the standard treatment for chronic hepatitis C. Sustained virological response (SVR) rates of up to 80% are reported in genotype 2 and 3 chronic hepatitis C cases. Obesity, a modifiable risk factor, may have a deleterious effect on antiviral treatment. We perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yeon Joo, Cho, Sung Bum, Park, Sang Woo, Hong, Hyoung Ju, Lee, Du Hyeon, Cho, Eun Ae, Kim, HyunSoo, Choi, Sung Kyu, Rew, Jong Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chonnam National University Medical School 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341433/
https://www.ncbi.nlm.nih.gov/pubmed/22570811
http://dx.doi.org/10.4068/cmj.2012.48.1.21
_version_ 1782231547691139072
author Kim, Yeon Joo
Cho, Sung Bum
Park, Sang Woo
Hong, Hyoung Ju
Lee, Du Hyeon
Cho, Eun Ae
Kim, HyunSoo
Choi, Sung Kyu
Rew, Jong Sun
author_facet Kim, Yeon Joo
Cho, Sung Bum
Park, Sang Woo
Hong, Hyoung Ju
Lee, Du Hyeon
Cho, Eun Ae
Kim, HyunSoo
Choi, Sung Kyu
Rew, Jong Sun
author_sort Kim, Yeon Joo
collection PubMed
description Pegylated-interferon plus ribavirin is the standard treatment for chronic hepatitis C. Sustained virological response (SVR) rates of up to 80% are reported in genotype 2 and 3 chronic hepatitis C cases. Obesity, a modifiable risk factor, may have a deleterious effect on antiviral treatment. We performed this study to examine the efficacy and safety of pegylated-interferon and ribavirin therapy in Korean patients with genotype 2 and 3 chronic hepatitis C and to investigate the risk factors for nonresponse to antiviral treatment. A total of 121 patients were treated with peginterferon alpha-2a 180 mcg/week plus ribavirin 800 mg/day for 24 weeks. The end-of-treatment virologic response (ETVR), the SVR, the end-of-treatment biochemical response (ETBR), the sustained biochemical response (SBR), and the adverse events were analyzed. The ETVR and SVR were 94.1% and 89.1%, respectively. The ETBR was 80.2% and the SBR was 96%. Multivariate analysis showed that a body mass index of 25 and over was the only independent factor that affected the SVR (odds ratio=10.5, 95% confidence interval: 2.006-54.948, p=0.005). Twenty patients (16.5%) dropped out at the end of treatment, and 7 (5.8%) patients discontinued treatment because of treatment-related adverse events. Our study showed that combination therapy with pegylated-interferon and ribavirin as an initial treatment for genotype 2 and 3 chronic hepatitis C is very effective and safe, and that body mass index is an independent risk factor for nonresponse to antiviral treatment in patients with genotype 2 and 3 chronic hepatitis C.
format Online
Article
Text
id pubmed-3341433
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Chonnam National University Medical School
record_format MEDLINE/PubMed
spelling pubmed-33414332012-05-08 Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C Kim, Yeon Joo Cho, Sung Bum Park, Sang Woo Hong, Hyoung Ju Lee, Du Hyeon Cho, Eun Ae Kim, HyunSoo Choi, Sung Kyu Rew, Jong Sun Chonnam Med J Original Article Pegylated-interferon plus ribavirin is the standard treatment for chronic hepatitis C. Sustained virological response (SVR) rates of up to 80% are reported in genotype 2 and 3 chronic hepatitis C cases. Obesity, a modifiable risk factor, may have a deleterious effect on antiviral treatment. We performed this study to examine the efficacy and safety of pegylated-interferon and ribavirin therapy in Korean patients with genotype 2 and 3 chronic hepatitis C and to investigate the risk factors for nonresponse to antiviral treatment. A total of 121 patients were treated with peginterferon alpha-2a 180 mcg/week plus ribavirin 800 mg/day for 24 weeks. The end-of-treatment virologic response (ETVR), the SVR, the end-of-treatment biochemical response (ETBR), the sustained biochemical response (SBR), and the adverse events were analyzed. The ETVR and SVR were 94.1% and 89.1%, respectively. The ETBR was 80.2% and the SBR was 96%. Multivariate analysis showed that a body mass index of 25 and over was the only independent factor that affected the SVR (odds ratio=10.5, 95% confidence interval: 2.006-54.948, p=0.005). Twenty patients (16.5%) dropped out at the end of treatment, and 7 (5.8%) patients discontinued treatment because of treatment-related adverse events. Our study showed that combination therapy with pegylated-interferon and ribavirin as an initial treatment for genotype 2 and 3 chronic hepatitis C is very effective and safe, and that body mass index is an independent risk factor for nonresponse to antiviral treatment in patients with genotype 2 and 3 chronic hepatitis C. Chonnam National University Medical School 2012-04 2012-04-26 /pmc/articles/PMC3341433/ /pubmed/22570811 http://dx.doi.org/10.4068/cmj.2012.48.1.21 Text en © Chonnam Medical Journal, 2012 http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Yeon Joo
Cho, Sung Bum
Park, Sang Woo
Hong, Hyoung Ju
Lee, Du Hyeon
Cho, Eun Ae
Kim, HyunSoo
Choi, Sung Kyu
Rew, Jong Sun
Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C
title Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C
title_full Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C
title_fullStr Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C
title_full_unstemmed Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C
title_short Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C
title_sort body mass index and nonresponse to antiviral treatment in korean patients with genotype 2 and 3 chronic hepatitis c
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341433/
https://www.ncbi.nlm.nih.gov/pubmed/22570811
http://dx.doi.org/10.4068/cmj.2012.48.1.21
work_keys_str_mv AT kimyeonjoo bodymassindexandnonresponsetoantiviraltreatmentinkoreanpatientswithgenotype2and3chronichepatitisc
AT chosungbum bodymassindexandnonresponsetoantiviraltreatmentinkoreanpatientswithgenotype2and3chronichepatitisc
AT parksangwoo bodymassindexandnonresponsetoantiviraltreatmentinkoreanpatientswithgenotype2and3chronichepatitisc
AT honghyoungju bodymassindexandnonresponsetoantiviraltreatmentinkoreanpatientswithgenotype2and3chronichepatitisc
AT leeduhyeon bodymassindexandnonresponsetoantiviraltreatmentinkoreanpatientswithgenotype2and3chronichepatitisc
AT choeunae bodymassindexandnonresponsetoantiviraltreatmentinkoreanpatientswithgenotype2and3chronichepatitisc
AT kimhyunsoo bodymassindexandnonresponsetoantiviraltreatmentinkoreanpatientswithgenotype2and3chronichepatitisc
AT choisungkyu bodymassindexandnonresponsetoantiviraltreatmentinkoreanpatientswithgenotype2and3chronichepatitisc
AT rewjongsun bodymassindexandnonresponsetoantiviraltreatmentinkoreanpatientswithgenotype2and3chronichepatitisc